Encore Concierge Medicine, a leader in personalized healthcare, today announced a strategic partnership with OpenDNA, an innovator in precision genomics, to provide patients with access to advanced AI-driven genetic risk tests.
Through this collaboration, Encore Concierge Medicine will offer OpenDNA’s CardioRisk+, CancerRisk+, and TotalRisk+ tests, which combine polygenic and monogenic insights with clinical data to deliver a comprehensive view of individual health risks. These physician-ordered tests are designed to guide proactive, preventative, and personalized care.
“This partnership perfectly aligns with our mission to provide the highest standard of concierge medicine,” said Dr. Julia Gold, Founder and Lead Physician of Encore Concierge Medicine. “By integrating OpenDNA’s advanced genetic risk assessments into our practice, we offer patients unparalleled insights into their health, empowering them to make informed decisions for a longer, healthier life.”
OpenDNA’s AI-powered technology analyzes genetic and clinical data to identify health risks with exceptional precision. By integrating these insights into concierge medicine, physicians can tailor health recommendations based on each patient’s unique profile. CardioRisk+ focuses on cardiovascular predispositions, CancerRisk+ evaluates cancer risk, and TotalRisk+ provides a full-spectrum genetic and clinical risk assessment.
“We are thrilled to partner with Encore Concierge Medicine to bring our AI-driven genetic risk tests to their patients,” said Dr. Eran Feldhay, CEO of OpenDNA. “Together, we are making personalized, preventive medicine more accessible and actionable than ever.”
The integration of OpenDNA’s AI-driven genetic risk tests into Encore Concierge Medicine’s services represents a significant advancement in concierge healthcare, setting a new benchmark for precision-driven, patient-centered care.
